Loading clinical trials...

The Remote Monitoring of Gout Feasibility Study | Clinical Trials | Clareo Health

COMPLETEDNA

The Remote Monitoring of Gout Feasibility Study

The ReMonit Gout Feasibility Study

NCT06211322•Diakonhjemmet Hospital

Summary

In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested.

Detailed Description

In this feasibility study various outcome measures will be assessed to determine whether the app (Urika) is viable, practical, and useful. The study will include assessments of technical, operational, clinical, and trial aspects of feasibility.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or non-pregnant, non-nursing female \>18 years of age at screening
•Patients with a clinical diagnosis of gout
•Patients who fulfil the American College of Rheumatology (ACR)/EULAR classification criteria
•Serum urate level \>360 μmol/L at inclusion
•Having a smartphone/tablet

Exclusion Criteria

•Contraindication for urate lowering therapy
•Unstable medical conditions (e.g,, uncontrollable hypertension, impaired liver function); known stage 3b or higher chronic kidney disease (estimated glomerular filtration (eGFR) rate/creatinine clearance \<45 mL/min); severe infection or gastrointestinal bleed
•Major co-morbidities (e.g., malignancies, severe cardiovascular disease, severe diabetes mellitus, severe respiratory diseases)
•Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult

Locations (1)

Diakonhjemmet Hospital

Oslo, Norway

Key Dates

Start Date

February 27, 2024

Primary Completion Date

September 26, 2024

Completion Date

October 11, 2024

Last Updated

December 11, 2024

Enrollment

ACTUAL participants

Conditions

Gout

Interventions

"Urika", a self-management application for patients with gout

DEVICE

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875

Gout

View study

RECRUITINGPHASE2

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746

GoutGouty Arthritis+5 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 11, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Remote Monitoring of Gout Feasibility Study

Inclusion Criteria

Exclusion Criteria

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

The Myelin Disorders Biorepository Project

Clinical Efficacy Trial of Burdock Root Extract in Patients With Asymptomatic Hyperuricaemia

Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout